The DOI matches its Crossref record.
Multidrug Resistance: Retrospect and Prospects in Anti-Cancer Drug Treatment
Abstract
Conventional cancer chemotherapy is seriously limited by the multidrug resistance (MDR) commonly exhibited by tumour cells. One mechanism by which a living cell can achieve multiple resistances is via the active efflux of a broad range of anticancer drugs through the cellular membrane by MDR proteins. Such drugs are exported in both ATP-dependent and -independent manners, and can occur despite considerable concentration gradients. To the ATP-dependent group belongs the ATP-binding cassette (ABC) transporter family, which includes P-gp, MRP, BCRP, etc. Another protein related to MDR, though not belonging to the ABC transporter family, is lung resistance-related protein (LRP). All of these proteins are involved in diverse physiological processes, and are responsible for the uptake and efflux of a multitude of substances from cancer cells. Many inhibitors of MDR transporters have been identified over the years. Firstly, MDR drugs were not specifically developed for inhibiting MDR; in fact, they had other pharmacological properties, as well as a relatively low affinity for MDR transporters. They included compounds of diverse structure and function, such as verapamil and cyclosporine, and caused side effects. Secondly, the new drugs were more inhibitor-specific, in terms of MDR transport, and were designed to reduce such side effects (e.g., R-verapamil, dexniguldipine, etc.). Unfortunately, they displayed poor response in clinical studies. Recently, new compounds obtained from drug development programs conducted by the pharmaceutical industry are characterized by a high affinity to MDR transporters and are efficient at nanomolar concentrations. Some of these compounds (e.g., MS-209) are currently under clinical trials for specific forms of advanced cancers. We aim to provide an overview of the properties associated with those mammalian MDR transporters known to mediate significant transport of relevant drugs in cancer treatments. We also summarize recent advances concerning resistance to cancer drug therapies with respect to the function and overexpression of ABC and LRP multidrug transporters.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Blood-Testis Barrier and Its Implications for Male Contraception
Cheng, C. Y., & Mruk, D. D. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.002790 · Cited by 927
Ge, Z., & Liu, S. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60048c · Cited by 914
From antimicrobial to anticancer peptides. A review
Gaspar, D., Veiga, A. S., & Castanho, M. A. R. B. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00294 · Cited by 749
Apoptosis and glutathione: beyond an antioxidant
Franco, R., & Cidlowski, J. A. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2009.107 · Cited by 744
Metronomic chemotherapy: new rationale for new directions
Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 659
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596
The central role of glutathione in the pathophysiology of human diseases
Franco, R., Schoneveld, O. J., Pappa, A., & Panayiotidis, M. I. (2007) · Archives of Physiology and Biochemistry · doi:10.1080/13813450701661198 · Cited by 536
Cationic amphiphilic peptides with cancer-selective toxicity
Schweizer, F. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.043 · Cited by 517
Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?
Callaghan, R., Luk, F., & Bebawy, M. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.056176 · Cited by 453
Kretschmer, M., Leroch, M., Mosbach, A., Walker, A.-S., Fillinger, S., Mernke, D., Schoonbeek, H.-J., Pradier, J.-M., Leroux, P., De Waard, M. A., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000696 · Cited by 419
Riedl, S., Zweytick, D., & Lohner, K. (2011) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2011.09.004 · Cited by 405
Lactate in the Tumor Microenvironment: An Essential Molecule in Cancer Progression and Treatment
Pérez-Tomás, R., & Pérez-Guillén, I. (2020) · Cancers · doi:10.3390/cancers12113244 · Cited by 385
Glutathione-Depleting Nanomedicines for Synergistic Cancer Therapy
Cheng, X., Xu, H.-D., Ran, H.-H., Liang, G., & Wu, F.-G. (2021) · ACS Nano · doi:10.1021/acsnano.1c00498 · Cited by 374
Mi, Y.-J., Liang, Y.-J., Huang, H.-B., Zhao, H.-Y., Wu, C.-P., Wang, F., Tao, L.-Y., Zhang, C.-Z., Dai, C.-L., Tiwari, A. K., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0111 · Cited by 337
Chemoresistance mechanisms of breast cancer and their countermeasures
Ji, X., Lu, Y., Tian, H., Meng, X., Wei, M., & Cho, W. C. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108800 · Cited by 340
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy
Silva, R., Vilas-Boas, V., Carmo, H., Dinis-Oliveira, R. J., Carvalho, F., de Lourdes Bastos, M., & Remião, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.013 · Cited by 339
Positron emission tomography molecular imaging for drug development
Matthews, P. M., Rabiner, E. A., Passchier, J., & Gunn, R. N. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04085.x · Cited by 320
The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer
Thapa, R., & Wilson, G. D. (2016) · Stem Cells International · doi:10.1155/2016/2087204 · Cited by 312
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9399-1 · Cited by 303
Peetla, C., Vijayaraghavalu, S., & Labhasetwar, V. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.004 · Cited by 289
Structural Simplification of Natural Products
Wang, S., Dong, G., & Sheng, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00504 · Cited by 254
Hippo pathway mediates resistance to cytotoxic drugs
Gujral, T. S., & Kirschner, M. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703096114 · Cited by 91
Zaja, R., Caminada, D., Lončar, J., Fent, K., & Smital, T. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.11.001 · Cited by 34
Metadata
- Authors
- Perez-Tomas, R.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-07-01
- Volume
- 13
- Issue
- 16
- Pages
- 1859-1876
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W1993766071
- Cited by
- 509
- References
- 0
- FWCI
- 13.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.